haduvio
Generic: oral nalbuphine ER
haduvio: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Trevi Therapeutics, Inc. (TRVI) | Phase 2/Phase 3 |
FDA Decisions
FDA_MeetingCompany expects to request an end of Phase 2 meeting in the second half of 2025 to align on the Phase 3 program for chronic cough in IPF patients.(TRVI)
Frequently asked questions
Who is developing haduvio?
haduvio is being developed by Trevi Therapeutics, Inc..
What is haduvio's latest FDA decision?
The most recent tracked FDA decision for haduvio is FDA_Meeting for Company expects to request an end of Phase 2 meeting in the second half of 2025 to align on the Phase 3 program for chronic cough in IPF patients..
Get deeper analysis on haduvio
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis